Peel Hunt reaffirmed their buy rating on shares of Clinigen Group (LON:CLIN) in a report released on Thursday morning.
CLIN has been the topic of several other research reports. Numis Securities reaffirmed a buy rating on shares of Clinigen Group in a research note on Wednesday, July 25th. UBS Group reaffirmed a buy rating and issued a GBX 1,160 ($15.16) price objective on shares of Clinigen Group in a research note on Thursday, September 27th. Finally, Royal Bank of Canada reaffirmed a top pick rating and issued a GBX 1,470 ($19.21) price objective (up previously from GBX 1,360 ($17.77)) on shares of Clinigen Group in a research note on Monday, October 15th. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Clinigen Group has an average rating of Buy and an average price target of GBX 1,265 ($16.53).
Shares of CLIN opened at GBX 906.88 ($11.85) on Thursday. Clinigen Group has a 12-month low of GBX 751.50 ($9.82) and a 12-month high of GBX 1,187 ($15.51).
The firm also recently disclosed a dividend, which will be paid on Friday, November 30th. Stockholders of record on Thursday, November 8th will be paid a GBX 3.84 ($0.05) dividend. The ex-dividend date of this dividend is Thursday, November 8th. This represents a dividend yield of 0.46%. This is a boost from Clinigen Group’s previous dividend of $1.76.
About Clinigen Group
Clinigen Group plc operates as a specialty pharmaceutical and services company. Its Clinigen Clinical Trial Services segment supplies and manages commercial medical products for use in clinical studies, including comparator drugs, adjuvant drugs, and rescue therapies. The company's Idis Managed Access segment is involved in the consultancy, development, management, and implementation of managed access programs for biotechnology and pharmaceutical companies.
Featured Article: How Do You Calculate Return on Equity (ROE)?
Receive News & Ratings for Clinigen Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group and related companies with MarketBeat.com's FREE daily email newsletter.